Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia

Area of Science:

• Neonatal Medicine
• Endocrinology
• Developmental Pediatrics

Background:

• Extremely premature infants often experience transient hypothyroxinaemia (low thyroid hormone levels) in early life.
• This condition is linked to increased neonatal morbidity, mortality, and long-term developmental issues.
• Thyroid hormone therapy is being explored as a potential intervention to mitigate these risks.

Purpose of the Study:

• To evaluate the efficacy of thyroid hormone therapy in preterm infants diagnosed with transient hypothyroxinaemia.
• To assess the impact of this therapy on neonatal outcomes and neurodevelopmental trajectories.
• To determine if thyroid hormone supplementation can prevent adverse effects associated with low thyroid hormone levels in preterm neonates.

Main Methods:

• A comprehensive literature search was conducted across multiple databases, including CENTRAL, MEDLINE, EMBASE, and conference proceedings.
• Eligible trials included preterm infants with transient hypothyroxinaemia (low thyroid hormone, normal TSH) randomly assigned to thyroid hormone therapy or a control group (placebo/no treatment).
• Data were extracted and analyzed using standard Cochrane Collaboration methods, calculating relative risks and weighted mean differences.

Main Results:

• Only one eligible study, involving 23 infants, was identified.
• The study found no significant differences in neonatal mortality, bronchopulmonary dysplasia, or other major morbidities between thyroxine and placebo groups.
• No significant differences in growth parameters or thyroid hormone levels were observed, and neurodevelopmental follow-up was inadequate.

Conclusions:

• There is insufficient evidence to support the use of thyroid hormones for treating transient hypothyroxinaemia in preterm infants.
• The current evidence does not demonstrate improvements in neonatal morbidity and mortality or reductions in neurodevelopmental impairments.
• Further rigorous research is necessary to establish the role and safety of thyroid hormone therapy in this population.